Comparing the current results to its competitors, Adial Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 29.63 %, recorded in the same quarter.
Adial Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -87.96 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -87.96 %
Adial Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company holds an exclusive worldwide license to three patent families covering the use of ondansetron to treat four specified genotypes for alcohol use disorder (AUD), with patent protection expected through 2031. A new patent filed in 2025, owned by Adial, may extend protection to 2045. The low dose of ondansetron used in AD04 (0.33 mg) has not been previously approved. The company asserts that its patents will protect against competitors marketing similar low doses. Off-label use of existing ondansetron products such as Zofran® (4 mg and 8 mg tablets) is considered unlikely to affect AD04 sales due to dosing impracticalities and safety concerns. The company believes its patent protection is sufficient to prevent competitors from launching generic versions of AD04, as marketing the AD04 dose would infringe on their patents. While competitors could theoretically avoid infringement by conducting separate clinical trials for different indications, no such programs are currently known, rendering this risk negligible.
November 14, 2024
In a significant advancement in the treatment of alcohol use disorder (AUD), Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, recently reported positive topline results from its AD04-103 pharmacokinetics study of AD04, a novel therapeutic agent designed to address addiction and related disorders. The study findings suggest that AD04 exhibits a confirmed relative bioavailability compared to the reference standard, with evidence of dose-proportional increases in pharmacokinetic exposure and no notable food effect.Pharmacokinetics, the study of how a drug is absorbed, distributed, metabolized, and excreted in the body, is a critical area of research in drug development. Th...
July 23, 2024
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderAdial Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of innovative treatments for alcohol use disorder (AUD), has recently announced the commencement of patient dosing in the second cohort of its pharmacokinetics study for AD04, a potential treatment for AUD.This significant development comes on the heels of the successful completion of the first cohort, indicating promising progress in the evaluation of AD04 s efficacy and safety profile. The pharmacokinetics study aims to determine the concentration of AD04 in the blood over time, helping to iden...
December 20, 2023
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on addiction therapeutics, has recently announced the receipt of the final development cost reimbursement payment of $350,000 from Adovate, LLC. This payment marks a significant milestone in their business agreement and sets the stage for potential groundbreaking discoveries in addiction and related disorders. In addition to this immediate injection of funds, Adial Pharmaceuticals stands to gain up to $83 million in total consideration, including milestone payments and equity stakes in Adovate.The Asset Purchase AgreementThe payment received by Adial Pharmaceuticals is part of the asset purchase agreement executed with Adovate for the...
Publicly Traded Peers of Adial Pharmaceuticals Inc
Avid Bioservices Inc Share Performance
+99.20%
One Year
Avid Bioservices Inc
Profile
Avid Bioservices Inc is a biopharmaceutical company that provides contract development and manufacturing services for the production of biologics, including antibodies and mammalian cell-based therapies, to pharmaceutical and biotechnology companies.
Neurocrine Biosciences Inc's business model involves researching, developing, and commercializing innovative therapies for neurological and endocrine disorders.
Sources:
Adial Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adial Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
